Skip to content

Mechanism research of dexmedetomidine in the treatment of postherpetic neuralgia by promoting MDSC apoptosis and inhibiting p75

Mechanism research of dexmedetomidine in the treatment of postherpetic neuralgia by promoting MDSC apoptosis and inhibiting p75

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024265
Enrollment
Unknown
Registered
2019-07-03
Start date
2019-08-01
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

Sponsors

Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) those who meet the diagnostic criteria for postherpetic neuralgia (2) aged 18 to 80 years; (3) body mass index (BMI) ranged from 18.0 to 25.0 (including 18.0 years old and 25.0 years old); (4) VAS score of 4-10 points (including 4 points and 10 points); (5) no satisfactory remission for at least 1 month after conservative pain treatment (e.g., antidepressants, anticonvulsants, tramadol, opioids, nerve block or damage, radiofrequency conditioning or damage); (6) voluntarily participate in the study and have signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) people who are known to be allergic to dexmedetomidine and ketorolac amantinol; (2) inability to cooperate, such as lethargy, coma, confusion, delirium; (3) having a history of alcohol or drug abuse; (4) participants who have participated in other clinical trials within 12 weeks prior to or before the trial; (5) patients with pain syndrome (such as complex regional pain syndrome, spinal cord injury, diabetic multiple neuropathy, fibromyalgia); (6) patients with severe systemic diseases (including hypertension grade 2 or above, diabetes, myasthenia gravis, severe renal impairment, severe pulmonary dysfunction, shock, severe liver dysfunction, acute heart failure); (7) patients with infectious diseases (i.e. HIV, hepatitis b, syphilis); (8) severely infected; (9) patients with malignant tumors; (10) mental disorders (such as somatization disorders, schizophrenia, mania); (11) resting heart rate 100 times/min after ecg screening.

Design outcomes

Primary

MeasureTime frame
T cell;Myeloid-derived suppressor cells;apolipoprotein E;

Secondary

MeasureTime frame
Visual analogue score value;Depression score;

Countries

China

Contacts

Public ContactQun Li

Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University

quner1984@163.com+86 13982767559

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026